Literature DB >> 27376648

[HER2 testing in gastric cancer : Results of a meeting of German experts].

G Baretton1, M Dietel2, T Gaiser3, T Kirchner4, H H Kreipe5, A Quaas6, C Röcken7, J Rüschoff8, A Tannapfel9, F Lordick10, S Al-Batran11, R Hofheinz12, S Lorenzen13, M Moehler14, P Thuss-Patience15.   

Abstract

Valid HER2 testing is essential for the optimal care of patients with HER2-positive gastric cancer and the correct use of first-line treatment. Although all cases of breast cancer are routinely tested for the HER2 status, HER2 testing in gastric cancer has still not become part of the routine and is usually only done upon request by the therapist. An interdisciplinary group of German experts has taken on the challenges of HER2 testing in gastric cancer as an opportunity to address essential aspects and questions on the practical use of HER2 testing in this indication from the perspective of pathologists and therapists. The recommendations made in this article reflect the consensus of all participants and correspond to their opinions and long-term experience.

Entities:  

Keywords:  Consensus; Gastric cancer; HER2 testing; Quality assurance; Trastuzumab

Mesh：

Substances：

Year:  2016        PMID： 27376648     DOI： 10.1007/s00292-016-0179-3

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


  18 in total

1.  [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].

Authors:  M Moehler; S-E Al-Batran; T Andus; M Anthuber; J Arends; D Arnold; D Aust; P Baier; G Baretton; J Bernhardt; H Boeing; E Böhle; C Bokemeyer; J Bornschein; W Budach; E Burmester; K Caca; W A Diemer; C F Dietrich; M Ebert; A Eickhoff; C Ell; J Fahlke; H Feussner; R Fietkau; W Fischbach; W Fleig; M Flentje; H E Gabbert; P R Galle; M Geissler; I Gockel; U Graeven; L Grenacher; S Gross; J T Hartmann; M Heike; V Heinemann; B Herbst; T Herrmann; S Höcht; R D Hofheinz; H Höfler; T Höhler; A H Hölscher; M Horneber; J Hübner; J R Izbicki; R Jakobs; C Jenssen; S Kanzler; M Keller; R Kiesslich; G Klautke; J Körber; B J Krause; C Kuhn; F Kullmann; H Lang; H Link; F Lordick; K Ludwig; M Lutz; R Mahlberg; P Malfertheiner; S Merkel; H Messmann; H-J Meyer; S Mönig; P Piso; S Pistorius; R Porschen; T Rabenstein; P Reichardt; K Ridwelski; C Röcken; I Roetzer; P Rohr; W Schepp; P M Schlag; R M Schmid; H Schmidberger; W-H Schmiegel; H-J Schmoll; G Schuch; C Schuhmacher; K Schütte; W Schwenk; M Selgrad; A Sendler; J Seraphin; T Seufferlein; M Stahl; H Stein; C Stoll; M Stuschke; A Tannapfel; R Tholen; P Thuss-Patience; K Treml; U Vanhoefer; M Vieth; H Vogelsang; D Wagner; U Wedding; A Weimann; H Wilke; C Wittekind
Journal:  Z Gastroenterol       Date:  2011-04-07       Impact factor: 2.000

2.  [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].

Authors:  J Rüschoff; I Nagelmeier; G Baretton; M Dietel; H Höfler; H U Schildhaus; R Büttner; W Schlake; O Stoss; H H Kreipe
Journal:  Pathologe       Date:  2010-05       Impact factor: 1.011

3.  Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.

Authors:  Farin Kamangar; Graça M Dores; William F Anderson
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

4.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Authors:  M Tanner; M Hollmén; T T Junttila; A I Kapanen; S Tommola; Y Soini; H Helin; J Salo; H Joensuu; E Sihvo; K Elenius; J Isola
Journal:  Ann Oncol       Date:  2005-02       Impact factor: 32.976

5.  Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).

Authors:  Sook Ryun Park; Young Soo Park; Min-Hee Ryu; Baek-Yeol Ryoo; Chang Gok Woo; Hwoon-Yong Jung; Jeong Hoon Lee; Gin Hyug Lee; Yoon-Koo Kang
Journal:  Eur J Cancer       Date:  2015-12-13       Impact factor: 9.162

6.  Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.

Authors:  Takuo Takehana; Kazuyoshi Kunitomo; Koji Kono; Fumiaki Kitahara; Hidehiko Iizuka; Yoshiro Matsumoto; Masayuki A Fujino; Akishi Ooi
Journal:  Int J Cancer       Date:  2002-04-20       Impact factor: 7.396

7.  Assessment of a HER2 scoring system for gastric cancer: results from a validation study.

Authors:  M Hofmann; O Stoss; D Shi; R Büttner; M van de Vijver; W Kim; A Ochiai; J Rüschoff; T Henkel
Journal:  Histopathology       Date:  2008-04-18       Impact factor: 5.087

Review 8.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Authors:  C Gravalos; A Jimeno
Journal:  Ann Oncol       Date:  2008-04-25       Impact factor: 32.976

9.  Quality assessment of HER2 testing by monitoring of positivity rates.

Authors:  Harald Choritz; Guntram Büsche; Hans Kreipe
Journal:  Virchows Arch       Date:  2011-08-02       Impact factor: 4.064

10.  Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer.

Authors:  Irene Gullo; Federica Grillo; Luca Molinaro; Matteo Fassan; Annalisa De Silvestri; Carmine Tinelli; Massimo Rugge; Roberto Fiocca; Luca Mastracci
Journal:  Endosc Int Open       Date:  2015-02-03
View more
  3 in total

Review 1.  Predictive biomarkers in gastric cancer.

Authors:  C Röcken
Journal:  J Cancer Res Clin Oncol       Date:  2022-10-19       Impact factor: 4.322

Review 2.  [Nuclear Her2 expression in hepatocytes in liver disease].

Authors:  P Döring; G M Pilo; D F Calvisi; F Dombrowski
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

3.  Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.

Authors:  Andreas H Scheel; Frédérique Penault-Llorca; Wedad Hanna; Gustavo Baretton; Peter Middel; Judith Burchhardt; Manfred Hofmann; Bharat Jasani; Josef Rüschoff
Journal:  Diagn Pathol       Date:  2018-03-12       Impact factor: 2.644
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.